Close Menu

NEW YORK ─ Maxim Biomedical this week is evaluating data from an undisclosed number of symptomatic and asymptomatic SARS-CoV-2 patient samples as part of a clinical study to validate a single-use antigen test it believes would provide results at the point of care in 15 minutes.

The firm expects that the data from its validation study will enable it to apply within two weeks to the US Food and Drug Administration for Emergency Use Authorization, Jonathan Maa, the company's chief operating officer, said in an interview.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.